The ROE as of November 2024 (TTM) for Aeglea BioTherapeutics, Inc. (AGLE) is 113.61%

According to Aeglea BioTherapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 113.61%. This represents a change of 1.47% compared to the average of 7.22% of the last 4 quarters.

Aeglea BioTherapeutics, Inc. (AGLE) Historical ROE (quarterly & annually)

How has AGLE ROE performed in the past?

The mean historical ROE of Aeglea BioTherapeutics, Inc. over the last ten years is -116.68%. The current 113.61% ROE has changed -197.37% with respect to the historical average. Over the past ten years (40 quarters), AGLE's ROE was at its highest in in the June 2023 quarter at 104.68%. The ROE was at its lowest in in the December 2014 quarter at -169.93%.

Aeglea BioTherapeutics, Inc. (AGLE) ROE by Quarter and Year

Discovering the peaks and valleys of Aeglea BioTherapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Aeglea BioTherapeutics, Inc. (AGLE) Average ROE

How has AGLE ROE performed in the past?

The current ROE of Aeglea BioTherapeutics, Inc. (AGLE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Aeglea BioTherapeutics, Inc. (AGLE) ROE vs. Peers

How is AGLE’s ROE compared to its peers?

Aeglea BioTherapeutics, Inc.’s ROE is greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Ikena Oncology, Inc. (-39.59%), greater than Design Therapeutics, Inc. (-18.01%), greater than Xilio Therapeutics, Inc. (-214.74%), greater than Eliem Therapeutics, Inc. (-47.03%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than Landos Biopharma, Inc. (-73.00%), less than Apexigen, Inc. (48.27%), greater than Navidea Biopharmaceuticals, Inc. (-173.56%), greater than Angion Biomedica Corp. (-98.89%), greater than SAB Biotherapeutics, Inc. (-94.37%), greater than Senti Biosciences, Inc. (-154.84%), greater than Cingulate Inc. (-113174.53%), less than Bellicum Pharmaceuticals, Inc. (33.22%), greater than Hillstream BioPharma, Inc. (-172.28%), greater than Neoleukin Therapeutics, Inc. (-8.54%), greater than CytomX Therapeutics, Inc. (-41.34%), greater than Assembly Biosciences, Inc. (-121.46%), greater than Instil Bio, Inc. (-37.44%), greater than Nuvation Bio Inc. (-108.68%), greater than Applied Molecular Transport Inc. (-131.59%), greater than Catalyst Biosciences, Inc. (-107.89%), greater than Aileron Therapeutics, Inc. (-46.89%), less than Bio-Path Holdings, Inc. (2.62%), greater than Benitec Biopharma Inc. (-60.28%),

Build a custom stock screener for Aeglea BioTherapeutics, Inc. (AGLE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aeglea BioTherapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aeglea BioTherapeutics, Inc. (AGLE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aeglea BioTherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.